Marvel Biosciences Corp.
MRVL.V
TSX
| 01/31/2026 | 10/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 31.68% | -18.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.90% | -48.78% | |||
| Operating Income | -3.90% | 48.78% | |||
| Income Before Tax | 11.64% | 71.53% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 11.64% | 71.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.64% | 71.53% | |||
| EBIT | -3.90% | 48.78% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 13.64% | 73.17% | |||
| Normalized Basic EPS | 17.86% | 72.55% | |||
| EPS Diluted | 13.64% | 73.17% | |||
| Normalized Diluted EPS | 17.86% | 72.55% | |||
| Average Basic Shares Outstanding | 4.36% | 4.92% | |||
| Average Diluted Shares Outstanding | 4.36% | 4.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||